Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
GoodRx Holdings, Inc.
GDRX
NASDAQ·Healthcare·Medical - Healthcare Information Services·Mkt cap $1.1B
$3.05
▼ -0.33%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$1.77 - $5.81
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 39.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Largest price comparison network with real-time data from thousands of U.S. pharmacies
- Strong consumer brand and 100+ million annual active users driving network effects
- Proprietary pricing algorithms and data analytics capabilities
- Multi-sided marketplace creating switching costs and recurring revenue
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Stable outlook
Increasing consumer demand for healthcare cost transparency and savings tools
Value
Deep value opportunity - significant discount to Healthcare IT & Services peers
Momentum
Hot
+49.3% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying GDRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 5, 2026
MAY 6, 2026
Reported EPS of $0.07 vs $0.07 consensus (0.0% surprise). Revenue of $194.0M vs $185.4M expected (+4.6%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
0.0%
Next: Aug 5, 2026
Revenue trend · last 8Q
—
—
—
+3%
+1%
+0%
-2%
-4%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$200.6M
$195.3M
$198.6M
$203.0M
$203.1M
$196.0M
$194.8M
$194.0M
Margins · last 8Q
Gross
—
Operating
—
Profit
0.6%
Wall Street consensus
6 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
$3.50
▲ +14.8% vs $3.05
Latest: Citi · May 14, 2026
1 analyst covering